Bisoprolol je lek iz grupe beta blokatora, klase lekova koji se prvenstveno koriste za tretiranje kardiovaskularnih bolesti. On je selektivan za tip β1 adrenergičkog receptora. FDA je odobrila zahtev kompanije Duramed farmaceuti za Zebeta oralne tablete (Bisoprolol fumarat) 31. jula1992. Od tog vremena niz drugih kompanija su dobile odobrenje za proizvodnju ovog leka.[8]
Klinička upotreba
Bisoprolol se koristi za tretiranje: visokog krvnog pritiska (hipertenzije), redukovanog protoka krvi do srca i kongestivnog zatajenja srca. On služi kao preventivni tretman pre, i kao primarni tretman nakon srčanog udara. Njime se umanjuju šanse od ponovnog udara.[9][10][11] U slučaju srčane ishemije lek se koristi za redukovanje aktivnosti srčanog mišića i stoga umanjenje potražnja za kiseonikom i nutrijentima, tako da redukovano snabdevanje krvi još uvek može da bude dovoljno.[12][13][14]
↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID21948594.edit
↑Bühring KU, Sailer H, Faro HP, Leopold G, Pabst J, Garbe A (1986). „Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans”. J. Cardiovasc. Pharmacol.8 Suppl 11: S21–8. PMID2439794.
↑Leopold G (1986). „Balanced pharmacokinetics and metabolism of bisoprolol”. J. Cardiovasc. Pharmacol.8 Suppl 11: S16–20. PMID2439789.
↑Rosenberg, J.; Gustafsson, F. (2008). „Bisoprolol for congestive heart failure”. Expert Opinion on Pharmacotherapy9 (2): 293–300. DOI:10.1517/14656566.9.2.293. PMID18201151.
↑Amabile, G.; Serradimigni, A. (1987). „Comparison of bisoprolol with nifedipine for treatment of essential hypertension in the elderly: Comparative double-blind trial”. European heart journal8 Suppl M: 65–69. PMID2967187.
↑Thadani, U. (2004). „Current medical management of chronic stable angina”. Journal of cardiovascular pharmacology and therapeutics9 Suppl 1: S11–S29; quiz S29–9. PMID15378129.
↑Konishi, M.; Haraguchi, G.; Kimura, S.; Inagaki, H.; Kawabata, M.; Hachiya, H.; Hirao, K.; Isobe, M. (2010). „Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure”. Circulation journal : official journal of the Japanese Circulation Society74 (6): 1127–1134. PMID20354334.
↑Castagno, D.; Jhund, P. S.; McMurray, J. J. V.; Lewsey, J. D.; Erdmann, E.; Zannad, F.; Remme, W. J.; Lopez-Sendon, J. L. i dr.. (2010). „Improved survival with bisoprolol in patients with heart failure and renal impairment: An analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial”. European Journal of Heart Failure12 (6): 607–616. DOI:10.1093/eurjhf/hfq038. PMID20354032.